Cell-based model establishment for the discovery of new molecules that inhibit the degradation of altered sdhb and rescue its tumor suppressor function in ppgl

The University of Auckland Research Office has been awarded $130,000 under the Military Medical Research and Development program (CFDA 12.420) administered by the Defense Health Agency, with an award date of October 1, 2025, and a completion date of September 30, 2027. The project focuses on establishing cell-based models for discovering new molecular inhibitors capable of preventing the degradation of altered SDHB (succinate dehydrogenase complex iron-sulfur subunit B) and restoring its tumor suppressor function in paragangliomas and pheochromocytomas (PPGL). This research addresses oncology within the Defense Health Agency's broader mission to advance innovative biomedical solutions and transform healthcare through hypothesis-driven investigation.

The award represents a typical project-based grant under the Military Medical Research and Development program, which supports basic, applied, and advanced biomedical research with emphasis on translational outcomes and clinical relevance. The University of Auckland's demonstrated expertise in conducting complex scientific investigations and collaborating with U.S. research institutions positions it to deliver rigorous research outputs that advance understanding of cancer suppressor mechanisms and potential therapeutic interventions within the two-year performance period.